NaPro/Abbott Paclitaxel Licenses Settle Patent Dispute, Create “Tripwires”
Executive Summary
NaPro Biotherapeutics' annual paclitaxel capacity will reach 100 kg by the time of the expected U.S. launch in early 2002, CEO Leonard Shaykin said Nov. 30
You may also be interested in...
NaPro Selling Paclitaxel Line To Faulding To Focus On New Cancer Agents
NaPro is trading its generic paclitaxel business for $50 mil. in cash to invest in new cancer agents and projects based on its "gene editing" technology
NaPro Selling Paclitaxel Line To Faulding To Focus On New Cancer Agents
NaPro is trading its generic paclitaxel business for $50 mil. in cash to invest in new cancer agents and projects based on its "gene editing" technology
Ivax Says Paclitaxel Will Stay On Market Despite Appeals Court Ruling
FDA does not want to remove generic versions of Bristol-Myers Squibb's Taxol from the market, Ivax maintained following an appeals court ruling directing the agency to vacate the approval of Ivax' ANDA for paclitaxel